BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24002510)

  • 1. Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
    Pellagatti A; Benner A; Mills KI; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Verma A; McDonald EJ; Killick S; Hellström-Lindberg E; Bullinger L; Wainscoat JS; Boultwood J
    J Clin Oncol; 2013 Oct; 31(28):3557-64. PubMed ID: 24002510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
    Giachelia M; D'Alò F; Fabiani E; Saulnier N; Di Ruscio A; Guidi F; Hohaus S; Voso MT; Leone G
    Leuk Res; 2011 Apr; 35(4):465-71. PubMed ID: 20869114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome.
    Gueller S; Komor M; Nowak D; Baldus CD; de Vos S; Hoelzer D; Ottmann OG; Hofmann WK
    Exp Hematol; 2010 Sep; 38(9):718-32, 732.e1-6. PubMed ID: 20621626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?
    Zeidan AM; Prebet T; Saad Aldin E; Gore SD
    Expert Rev Hematol; 2014 Apr; 7(2):191-4. PubMed ID: 24559255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.
    Prall WC; Czibere A; Grall F; Spentzos D; Steidl U; Giagounidis AAN; Kuendgen A; Otu H; Rong A; Libermann TA; Germing U; Gattermann N; Haas R; Aivado M
    Int J Hematol; 2009 Mar; 89(2):173-187. PubMed ID: 19152102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
    Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Verma A; Norbury CJ; Hellström-Lindberg E; Wainscoat JS; Boultwood J
    Leukemia; 2010 Apr; 24(4):756-64. PubMed ID: 20220779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.
    Hofmann WK; Takeuchi S; Takeuchi N; Thiel E; Hoelzer D; Koeffler HP
    Leuk Res; 2006 Nov; 30(11):1347-53. PubMed ID: 16682076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification of Bone Marrow Clonal Cells from Patients with Myelodysplastic Syndrome via IGF-IR.
    He Q; Chang CK; Xu F; Zhang QX; Shi WH; Li X
    PLoS One; 2015; 10(10):e0140372. PubMed ID: 26469401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
    Lange T; Hubmann M; Burkhardt R; Franke GN; Cross M; Scholz M; Leiblein S; Al-Ali HK; Edelmann J; Thiery J; Niederwieser D
    Leukemia; 2011 Mar; 25(3):498-505. PubMed ID: 21135860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow.
    Hofmann WK; de Vos S; Komor M; Hoelzer D; Wachsman W; Koeffler HP
    Blood; 2002 Nov; 100(10):3553-60. PubMed ID: 12411319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
    Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A
    Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
    Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
    Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
    Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
    Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
    Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
    Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes.
    del Rey M; O'Hagan K; Dellett M; Aibar S; Colyer HA; Alonso ME; Díez-Campelo M; Armstrong RN; Sharpe DJ; Gutiérrez NC; García JL; De Las Rivas J; Mills KI; Hernández-Rivas JM
    Leukemia; 2013 Mar; 27(3):610-8. PubMed ID: 22936014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.
    Minetto P; Guolo F; Clavio M; De Astis E; Colombo N; Grasso R; Fugazza G; Sessarego M; Lemoli RM; Gobbi M; Miglino M
    Leuk Res; 2015 Aug; 39(8):866-73. PubMed ID: 26012361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative review of classification systems in myelodysplastic syndromes (MDS).
    Bennett JM
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
    Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
    Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.